[go: up one dir, main page]

GB2608397A8 - Gynecomastia treatment - Google Patents

Gynecomastia treatment Download PDF

Info

Publication number
GB2608397A8
GB2608397A8 GB2109385.1A GB202109385A GB2608397A8 GB 2608397 A8 GB2608397 A8 GB 2608397A8 GB 202109385 A GB202109385 A GB 202109385A GB 2608397 A8 GB2608397 A8 GB 2608397A8
Authority
GB
United Kingdom
Prior art keywords
gynecomastia
treatment
modulator
estrogen receptor
receptor modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB2109385.1A
Other versions
GB2608397B (en
GB2608397A (en
GB202109385D0 (en
Inventor
Chaitowitz Ilan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB2109385.1A priority Critical patent/GB2608397B/en
Publication of GB202109385D0 publication Critical patent/GB202109385D0/en
Priority to GB2206832.4A priority patent/GB2608500A/en
Priority to CA3222283A priority patent/CA3222283A1/en
Priority to PCT/EP2022/067796 priority patent/WO2023275088A1/en
Priority to KR1020237045152A priority patent/KR20240027623A/en
Priority to US18/574,806 priority patent/US20240366562A1/en
Priority to EP22740818.4A priority patent/EP4362927A1/en
Priority to MX2023015446A priority patent/MX2023015446A/en
Priority to IL309837A priority patent/IL309837A/en
Priority to AU2022301440A priority patent/AU2022301440A1/en
Priority to JP2023581029A priority patent/JP2024524489A/en
Publication of GB2608397A publication Critical patent/GB2608397A/en
Publication of GB2608397A8 publication Critical patent/GB2608397A8/en
Application granted granted Critical
Publication of GB2608397B publication Critical patent/GB2608397B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A selective estrogen receptor modulator and/or an aromatase inhibitor (A) for use in the treatment or prevention of gynecomastia, wherein said selective estrogen receptor modulator and/or aromatase inhibitor is/are administered combination with (B) an estrogen modulator, wherein said estrogen modulator is different to said selective estrogen receptor modulator.
GB2109385.1A 2021-06-29 2021-06-29 Gynecomastia treatment Active GB2608397B (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB2109385.1A GB2608397B (en) 2021-06-29 2021-06-29 Gynecomastia treatment
GB2206832.4A GB2608500A (en) 2021-06-29 2022-05-10 Treatment for hormone dependent cancer
EP22740818.4A EP4362927A1 (en) 2021-06-29 2022-06-28 Gynecomastia and/or mastalgia treatment
AU2022301440A AU2022301440A1 (en) 2021-06-29 2022-06-28 Gynecomastia and/or mastalgia treatment
KR1020237045152A KR20240027623A (en) 2021-06-29 2022-06-28 Treatment of gynecomastia and/or mastalgia
US18/574,806 US20240366562A1 (en) 2021-06-29 2022-06-28 Gynecomastia and/or mastalgia treatment
CA3222283A CA3222283A1 (en) 2021-06-29 2022-06-28 Gynecomastia and/or mastalgia treatment
MX2023015446A MX2023015446A (en) 2021-06-29 2022-06-28 Gynecomastia and/or mastalgia treatment.
IL309837A IL309837A (en) 2021-06-29 2022-06-28 Gynecomastia and/or mastalgia treatment
PCT/EP2022/067796 WO2023275088A1 (en) 2021-06-29 2022-06-28 Gynecomastia and/or mastalgia treatment
JP2023581029A JP2024524489A (en) 2021-06-29 2022-06-28 Treatment of gynecomastia and/or breast pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2109385.1A GB2608397B (en) 2021-06-29 2021-06-29 Gynecomastia treatment

Publications (4)

Publication Number Publication Date
GB202109385D0 GB202109385D0 (en) 2021-08-11
GB2608397A GB2608397A (en) 2023-01-04
GB2608397A8 true GB2608397A8 (en) 2025-02-19
GB2608397B GB2608397B (en) 2025-04-09

Family

ID=77179477

Family Applications (2)

Application Number Title Priority Date Filing Date
GB2109385.1A Active GB2608397B (en) 2021-06-29 2021-06-29 Gynecomastia treatment
GB2206832.4A Withdrawn GB2608500A (en) 2021-06-29 2022-05-10 Treatment for hormone dependent cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB2206832.4A Withdrawn GB2608500A (en) 2021-06-29 2022-05-10 Treatment for hormone dependent cancer

Country Status (1)

Country Link
GB (2) GB2608397B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150395A (en) * 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
MXPA06006834A (en) * 2003-12-15 2006-09-04 Besins Int Lab Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia.
EP1550440A1 (en) * 2003-12-15 2005-07-06 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
NL2000351C2 (en) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogen modulators.
EP2373305B1 (en) * 2008-12-11 2017-03-15 Besins Healthcare Luxembourg SARL Transdermal pharmaceutical compositions comprising a serm

Also Published As

Publication number Publication date
GB2608397B (en) 2025-04-09
GB2608500A (en) 2023-01-04
GB2608397A (en) 2023-01-04
GB202109385D0 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
CL2009001011A1 (en) Use of the compound 21-methoxy-17a-acetoxy-11ß- (4-n, n-dimethylaminophenyl) -19-norpregna-4,9-diene-3,20-dione (cdb-4124) to treat breast cancer; and use of the combination of cdb-4124 with an aromatase inhibitor.
CL2017000080A1 (en) Methods to treat cancer with tigit inhibitors and anticancer agents
MX2018007266A (en) Combinations for the treatment of cancer.
CL2011000916A1 (en) Use of a combination of an epoxy ketone peptide proteasome inhibitor or an acceptable pharmaceutical salt thereof, and one or more other therapeutic agents to treat cancer.
MX2021000847A (en) Methods of treating cancer with pi3k inhibitor, gdc-0077.
ZA202103429B (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
CL2008001782A1 (en) Use of a composition comprising a compound derived from heterocycle to treat or prevent the loss of intestinal flow; composition comprising said compound; and kit that includes the composition.
AU2018335486A8 (en) Combination therapy using a Chemokine Receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
MX2020011817A (en) Methods for treating lymphoma.
MX2019005450A (en) Pharmaceutical compositions and methods for the treatment of cancer.
MX2019013862A (en) Combination therapy.
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
MX2022014034A (en) Methods of treating covid-19 using bardoxolone methyl or analogs thereof.
MX2021004709A (en) Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor.
MX2022002337A (en) Modified tff2 polypeptides.
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
MX2020011738A (en) Use of calcifediol in bariatric surgery patients.
GB2608397A8 (en) Gynecomastia treatment
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
WO2022261467A9 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
WO2019195355A9 (en) Tablet or composition having n-acyl ethanolamine and cannabinoid
MX2022014003A (en) Treatment of prostate cancer with a combination of abiraterone acetate and niraparib.
MX2022005250A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies.
BR112018076935A2 (en) composition, drug and method for the treatment of chemotherapy-induced alopecia
MX2023015446A (en) Gynecomastia and/or mastalgia treatment.